<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816607</url>
  </required_header>
  <id_info>
    <org_study_id>REK-2013/152</org_study_id>
    <secondary_id>REK-2013/152</secondary_id>
    <nct_id>NCT01816607</nct_id>
  </id_info>
  <brief_title>Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness</brief_title>
  <acronym>OxyTarget</acronym>
  <official_title>Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish a reliable method for detection of rectal cancer
      patients with aggressive tumor at risk of metastatic disease and death by functional MRI.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of metastatic disease 5 years after rectal cancer treatment</measure>
    <time_frame>five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histomorphological response to preoperative chemoradiotherapy</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Detection of regional malignant lymph nodes at time of diagnosis</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Rectal Diseases</condition>
  <condition>Rectal Neoplasms</condition>
  <condition>Gastrointestinal Diseases</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Rectal cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>new functional magnetic resonance imaging (MRI) protocols</intervention_name>
    <description>diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI</description>
    <arm_group_label>Rectal cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, rectal cancer tissue, normal tissue, lymph nodes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Rectal cancer patients referred to radical surgery, with or without preoperative
        chemoradiotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is willing and able to give full written consent according to the protocol
             approved by the Regional Ethics Committee.

          -  The patient has confirmed rectal cancer diagnosis and is scheduled to radical surgery
             alone or preoperative CRT followed by surgery.

          -  The patient is ≥ 18 years.

          -  The patient has no prior rectal cancer treatment.

          -  The patient has adequate renal function: creatinine clearance ≥ 60 ml/minute.

          -  The patient has signed the written informed consent according to the protocol approved
             by the Regional Ethics Committee.

        Exclusion Criteria:

          -  The patient has contraindication to MRI or MRI contrast agent according to clinical
             practice.

          -  The patient wants to withdraw for any reason during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathrine Røe, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathrine Røe, PhD</last_name>
    <phone>+4792437646</phone>
    <email>kathrine.roe@ahus.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne H Ree, MD, PhD</last_name>
    <email>a.h.ree@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrine Røe, PhD</last_name>
      <phone>+4792437646</phone>
      <email>kathrine.roe@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Kathrine Røe, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne H Ree, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Negård, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arne S Borthne, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arne E Færden, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Solveig N Andersen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Kathrine Røe</investigator_full_name>
    <investigator_title>Postdoctoral researcher</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Magnetic Resonance Imaging, Functional</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Rectal Diseases</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

